Holen Sie sich die Stockscreener-App
0.00
100.00%
-9.02
Range Cancer Therapeutics Etf Aktie (CNCR) Neueste Nachrichten
Investing in the DNA of Tomorrow: Explore Gene Stocks and Genomics ETFs - Investing News Network
Exploring the SPDR S&P Biotech ETF (XBI) for Biotech Industry Exposure - AInvest
4 Cancer Stocks to Consider in 2025 - The Motley Fool
When the Price of (CNCR) Talks, People Listen - news.stocktradersdaily.com
ICE to Expand NYSE Index Family With Launch of U.S. Tech Index and Broader Range of NYSE-Listed Indices - The Globe and Mail
The Best Biotech Stocks to Buy - Morningstar
When (CNCR) Moves Investors should Listen - news.stocktradersdaily.com
5 Small-cap Biotech ETFs to Watch - Investing News Network
Percheron Acquires Cancer Therapy Licence - Sharecafe
Where are the Opportunities in (CNCR) - news.stocktradersdaily.com
Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs - The Globe and Mail
(CNCR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor - Yahoo Finance
This ETF Could Turn $500 Per Month Into a $851,000 Portfolio Paying $30,000 in Annual Dividend Income - The Globe and Mail
Summit stock down after cancer trial data (update) (NASDAQ:SMMT) - Seeking Alpha
Friday's big stock stories: What’s likely to move the market in the next trading session - CNBC
ETF Channel: Range Cancer Therapeutics ETF Implied Analyst Target Price $20.61, Upside 132.35% - AInvest
Trend Tracker for (CNCR) - news.stocktradersdaily.com
Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA - Yahoo Finance
CIBC Asset Management launches three new actively managed CIBC ETFs, expanding its cash management and fixed income ETF suite - The Globe and Mail
Avacta Group Announces Investor Webinar on Latest Cancer Therapy Developments - TipRanks
Weekly ETF Industry Recap: U.S., Europe, and Canada HighlightsMay 5-10, 2025 - Trackinsight
Exchange Traded Concepts to Close and Liquidate the Range Cancer Therapeutics ETF - The Joplin Globe
Learn to Evaluate (CNCR) using the Charts - news.stocktradersdaily.com
Cold Spring Harbor Laboratory’s Ludmila Pollock lauded as fellow of AAAS - TBR News Media
Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance
Cathie Wood Bets on Nvidia, AMD Despite Chip Curbs and Dumps Microsoft Stock - The Globe and Mail
Long Term Trading Analysis for (CNCR) - news.stocktradersdaily.com
7 Best Pharmaceutical Stocks to Buy for Income | Investing - US News Money
From Panic to Positioning: Top ETFs to Watch After Asia’s Tariff Shock - The Globe and Mail
(CNCR) Investment Report - news.stocktradersdaily.com
10 Best Health Care Stocks to Buy for 2025 - US News Money
7 Top Gene-Editing Stocks to Buy | Investing | U.S. News - Money/ US News
Best Stocks Under $20 Right Now - Benzinga
Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - Nasdaq
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Nasdaq
QQQ ETF News, 3/19/2025 - The Globe and Mail
(CNCR) Proactive Strategies - Stock Traders Daily
Buffer ETFs to Consider for Protecting Gains and Limiting Losses - The Globe and Mail
S&P 500 Index Funds Yield Just 1.3%. Consider Buying These 2 Low-Cost Vanguard ETFs to Generate More Passive Income. - The Globe and Mail
Bull or Bear, These 2 ETFs Don’t Care - The Globe and Mail
VOO ETF News, 3/12/2025 - The Globe and Mail
Is the Fidelity High Dividend ETF the Smartest Investment You Can Make Today? - The Globe and Mail
Nasdaq Correction: Buy This Unstoppable ETF at a Discount - The Globe and Mail
SCHD ETF News, 3/11/2025 - The Globe and Mail
1 No-Brainer Artificial Intelligence (AI) ETF to Buy With $40 During the Nasdaq Sell-Off - The Globe and Mail
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance
Best Biotech Stocks to Buy in 2025 - The Motley Fool
(CNCR) Investment Analysis - news.stocktradersdaily.com
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Top ETFs to Invest in Japan - The Globe and Mail
Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025 - Investing News Network
The Unstoppable Momentum in Oncology M&A - Nasdaq
2025 Outlook: Healthcare Technology & Innovation - ETF Trends
The Best Way to Invest in Gold Is... - The Globe and Mail
SELLAS Life Sciences Group, Inc. Secures $25 Million in Registered Direct Offering for Cancer Therapeutics Development - Nasdaq
5 US Longevity and Anti-aging Stocks to Watch in 2025 - Investing News Network
NEW: The Most Popular Sponsored Content of 2024 - Visual Capitalist
Stocks to Watch in 2025: PHIO, LPTH, KAVL and more - Markets.com
Roche Executing Commercially, But R&D Productivity Remains A Work In Progress - Seeking Alpha
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises - Yahoo Finance
Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials - Yahoo Finance
(CNCR) Trading Report - news.stocktradersdaily.com
Moderna Inc. (MRNA): Among the Most Promising Cancer Stocks According to Hedge Funds - Yahoo Finance
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Disruptive Theme of the Week: Breakthroughs in Medicine - ETF Trends
Trackinsight ETF data from 11th to 15th November, 2024 - ETF Express
0.53%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):